JP2021534185A - スタチン治療対象における末梢動脈血行再建の必要性を低減する方法 - Google Patents

スタチン治療対象における末梢動脈血行再建の必要性を低減する方法 Download PDF

Info

Publication number
JP2021534185A
JP2021534185A JP2021507918A JP2021507918A JP2021534185A JP 2021534185 A JP2021534185 A JP 2021534185A JP 2021507918 A JP2021507918 A JP 2021507918A JP 2021507918 A JP2021507918 A JP 2021507918A JP 2021534185 A JP2021534185 A JP 2021534185A
Authority
JP
Japan
Prior art keywords
subject
baseline
study
patients
statin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534185A5 (cg-RX-API-DMAC7.html
Inventor
クレイグ グラノウィッツ,
セフィ フィリップ,
Original Assignee
アマリン ファーマシューティカルズ アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アマリン ファーマシューティカルズ アイルランド リミテッド filed Critical アマリン ファーマシューティカルズ アイルランド リミテッド
Publication of JP2021534185A publication Critical patent/JP2021534185A/ja
Publication of JP2021534185A5 publication Critical patent/JP2021534185A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2021507918A 2018-08-17 2019-08-15 スタチン治療対象における末梢動脈血行再建の必要性を低減する方法 Pending JP2021534185A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719404P 2018-08-17 2018-08-17
US62/719,404 2018-08-17
PCT/US2019/046710 WO2020037153A1 (en) 2018-08-17 2019-08-15 Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject

Publications (2)

Publication Number Publication Date
JP2021534185A true JP2021534185A (ja) 2021-12-09
JP2021534185A5 JP2021534185A5 (cg-RX-API-DMAC7.html) 2022-08-22

Family

ID=69524891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507918A Pending JP2021534185A (ja) 2018-08-17 2019-08-15 スタチン治療対象における末梢動脈血行再建の必要性を低減する方法

Country Status (17)

Country Link
US (2) US20220362200A1 (cg-RX-API-DMAC7.html)
EP (1) EP3836914A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021534185A (cg-RX-API-DMAC7.html)
KR (1) KR20210047312A (cg-RX-API-DMAC7.html)
CN (1) CN112912071A (cg-RX-API-DMAC7.html)
AU (2) AU2019321568B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002884A2 (cg-RX-API-DMAC7.html)
CL (3) CL2021000400A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190547A1 (cg-RX-API-DMAC7.html)
IL (1) IL280643A (cg-RX-API-DMAC7.html)
MA (1) MA52680A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021001906A (cg-RX-API-DMAC7.html)
NI (1) NI202100009A (cg-RX-API-DMAC7.html)
PH (1) PH12021550328A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101562UA (cg-RX-API-DMAC7.html)
TN (1) TN2021000028A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020037153A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US12430998B2 (en) 2018-09-14 2025-09-30 Avive Solutions, Inc. Device based responder network activation and virtual assistant integration
US11640755B2 (en) 2018-09-14 2023-05-02 Avive Solutions, Inc. Real time defibrillator incident data
US11645899B2 (en) 2018-09-14 2023-05-09 Avive Solutions, Inc. Responder network
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US20210153817A1 (en) * 2019-11-21 2021-05-27 Avive Solutions, Inc. Device based responder network activation and virtual assistant integration
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
EP4329742A4 (en) * 2021-04-29 2025-02-26 Amarin Pharmaceuticals Ireland Limited COMPOSITIONS COMPRISING EPA AND METHODS OF USE THEREOF FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544701A (ja) * 2006-07-21 2009-12-17 リライアント・ファーマシューティカルズ・インコーポレイテッド オメガ3脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
JP2015522029A (ja) * 2012-06-29 2015-08-03 アマリン ファーマシューティカルス アイルランド リミテッド スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
US20170333377A1 (en) * 2016-03-15 2017-11-23 Amarin Pharmaceuticals Ireland Limited Methods of Reducing or Preventing Oxidation of Small Dense LDL or Membrane Polyunsaturated Fatty Acids
US20180028505A1 (en) * 2016-07-29 2018-02-01 Kowa Company, Ltd. Methods of Preventing Cardiovascular Events in Residual Risk Dyslipidemic Populations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239927A1 (en) * 2004-12-06 2009-09-24 George Bobotas Statin and Omega-3 Fatty Acids For Lipid Therapy
CN114558129A (zh) * 2014-03-17 2022-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544701A (ja) * 2006-07-21 2009-12-17 リライアント・ファーマシューティカルズ・インコーポレイテッド オメガ3脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
JP2015522029A (ja) * 2012-06-29 2015-08-03 アマリン ファーマシューティカルス アイルランド リミテッド スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
US20170333377A1 (en) * 2016-03-15 2017-11-23 Amarin Pharmaceuticals Ireland Limited Methods of Reducing or Preventing Oxidation of Small Dense LDL or Membrane Polyunsaturated Fatty Acids
US20180028505A1 (en) * 2016-07-29 2018-02-01 Kowa Company, Ltd. Methods of Preventing Cardiovascular Events in Residual Risk Dyslipidemic Populations

Also Published As

Publication number Publication date
PH12021550328A1 (en) 2021-10-04
CA3109774A1 (en) 2020-02-20
AU2019321568B2 (en) 2025-01-30
SG11202101562UA (en) 2021-03-30
CN112912071A (zh) 2021-06-04
CL2021003222A1 (es) 2022-07-22
CL2021000400A1 (es) 2021-07-02
TN2021000028A1 (en) 2022-10-03
NI202100009A (es) 2021-06-22
EP3836914A4 (en) 2022-05-18
EA202190547A1 (ru) 2021-04-27
BR112021002884A2 (pt) 2021-05-11
EP3836914A1 (en) 2021-06-23
KR20210047312A (ko) 2021-04-29
US20220362200A1 (en) 2022-11-17
MA52680A1 (fr) 2021-11-30
IL280643A (en) 2021-03-25
AU2019321568A1 (en) 2021-03-11
WO2020037153A1 (en) 2020-02-20
CL2021003221A1 (es) 2022-07-22
AU2025202801A1 (en) 2025-05-08
MX2021001906A (es) 2021-04-28
AU2025202801A9 (en) 2026-03-05
US20250186386A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
JP7020756B2 (ja) 対象の心血管イベントのリスクを低減する方法
US20250186386A1 (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
TW202045154A (zh) 藉由增加血清及血漿epa及dpa含量來降低經他汀治療之受試者之心血管事件之風險的方法
CA3160827C (en) Methods of reducing the risk of cardiovascular events in a subject
US11986452B2 (en) Methods of reducing the risk of heart failure
CA3109774C (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
HK40079514B (en) Methods of reducing the risk of cardiovascular events in a subject
HK40079514A (en) Methods of reducing the risk of cardiovascular events in a subject
WO2024102429A1 (en) Methods of reducing risks of cardiovascular events in subjects with low baseline epa:aa ratio
HK40038227A (en) Methods of reducing the risk of cardiovascular events in a subject
HK40038229A (en) Methods of reducing the risk of cardiovascular events in a subject
HK40053699A (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220812

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240213